<html>
  <head>
    <meta charset="utf-8"/>
    <title>SAR - Summer 2023</title>
    <link rel="stylesheet" href="styles.css" />
  </head>
  
  <body>
    <div class="container">
      <div class="navigation">
        <div class="left-side">

            <div class="navigation-link">
              <a href="../index.html">Home</a>
            </div>
        </div>
        <div class="right-side">
          <div class="NameTag">
            <div>Huy Vo Huynh</div>
          </div>
        </div>
      </div>
      <div style="text-align: center;"><img src="../images/sar.png" style="height: 350px;"></div>
      <div class="content">
        <div class="portfolio-items">
          <div class="portfolio-item">
            <h1 style="color: red; padding-left: 15px;">SAR Analysis of PKCβ1 Inhibition by Selective Estrogen Receptor Modulators (SERMs)</h1>
            <p style="font-size: 20px; padding-left: 15px;"><em>Summer 2023</em></p>
          </div>
          <div class="line"></div>
          <div class="portfolio-item">
            <h2 style="margin-bottom: 0px;"><u>Program</u></h2>
            <p style="font-size: 20px; margin-top: 0px; padding-top: 5px;">SURF Program 2023 - Mayo Clinic, Rochester, Minnesota, USA</p>
            <h2 style="margin-bottom: 0px;"><u>Abstract</u></h2>
            <p style="font-size: 20px; margin-top: 0px; padding-top: 5px;">Protein kinases C (PKCs) participate in diverse cellular pathways including regulating cell growth. Z-Tamoxifen (Z-TAM) and its active metabolite Z-Endoxifen (Z-ENDX), both being selective estrogen receptor modulators (SERMs), have been shown to be inhibitors of protein kinase C beta 1 (PKCβ1), an isoform of the PKC family. However, Z-TAM has been previously indicated to be a less potent PKC inhibitor than Z-ENDX. Biochemical data from our lab has informed us that Z-ENDX interacts with both C- and N- domains of PKCβ1 in a non-competitive way with ATP, but the mechanistic insights into its binding are unknown. In this study, we perform structural activity relationships (SAR) analysis to compare inhibition of Z-ENDX and its derivatives and metabolites on PKCβ1. We determined IC50 values from a variety of ENDX-related SERMs with varying backbone configurations and functional groups. Overall, our data identify important features of SERMs structures for inhibiting PKCβ1, which is an important step in defining the molecular mechanism of how they bind and allosterically regulate PKCs. In future experiments, we aim to modify the structures of SERMs to increase specificity and potency for PKCs, which may lead to better anti-cancer therapies.</p>
            <h2 style="margin-bottom: 0px; "><u>Authors</u></h2>
            <p style="font-size: 20px;margin-top: 0px; padding-top: 5px;"><b>Huy V. Huynh</b>,  Jasmin K. Farmakes, Sayantani Sarkar Bhattacharya, Taylor L. Witter, Elizabeth S. Bruinsma, John R. Hawse IV, Matthew P. Goetz, and Matthew J. Schellenberg</p>
            <h2 style="margin-bottom: 0px; "><u>Techniques</u></h2>
            <p style="font-size: 20px; margin-top: 0px; padding-top: 5px;">Kinase Z-LYTE activity assay, mammalian cell cultures, affinity chromatography, size-exclusion chromatography, SDS-PAGE, western blotting, dose-response curve, proteolysis assay, protein X-ray crystallography</p>
            <h2 style="margin-bottom: 0px; "><u>Documentation</u></h2>
            <div class="container-for-rx">
              <div class="navigation-for-rx">
                <div class="left-side-for-rx">
                  <div class="navigation-link-for-rx">
                    <a href="https://github.com/HVKHCM/Capstone-Computer-Vision" target="__blank" >Code</a>
                  </div>
                  <div class="navigation-link-for-rx">
                    <a href="../../folder/Senior_Capstone.pdf" target="__blank">PDF</a>
                  </div>
                  <div class="navigation-link-for-rx">
                    <a href="../../folder/CV_final_pres.pdf" target="__blank">Slides</a>
                  </div>
            </div>
            </div>
            </div>
        </div>
        </div>


    </div>
  </body>
</html>